Диссертация (1141186), страница 26
Текст из файла (страница 26)
// J Clin Microbiol. – 2008.- v.46. – p.2106-2114.108. Hermine O., Lefrère F., Bronowicki J.P., Mariette X. Regression of splenic lymphoma with villouslymphocytes after treatment of hepatitis C virus infection. // N Engl J Med. – 2002. - v.347. – p.89-94.146109.
Inokuchi M., Ito T., Uchikoshi M., et al. Infection of B cells with hepatitis C virus for the developmentof lymphoproliferative disorders in patients with chronic hepatitis C. // J Med Virol. – 2009. – v.81. –p.619-627110. Invernizzi F., Galli M., Serino G. et al. Secondary and essential cryoglobulinemias. Frequency,nosological classification and long-term follow-up. // Acta Haematol. -1983. – v.70.
– p.73-82111. Ito M., Kusunoki H, Mochida K. HCV Infection and B-Cell Lymphomagenesis. // Adv Hematol. –2011. – p. 712-732.112. Jacobson I.M., Cacoub P., Dal Maso L. Manifestations of chronic hepatitis C virus infection beyondthe liver. // Clin Gastroenterol Hepatol. – 2010. – v.8. – p.1017-1046.113. Kayali Z., Buckwold V.E., Zimmerman B., Schmidt W.N. Hepatitis C, cryoglobulinemia and cirrhosis:a meta-analysis.
// Hepatology. – 2002. – v.36. - 978985.114. Kemmer N.M., Sherman K.E. Hepatitis C-related arthropathy: Diagnostic and treatment considerations.// J Musculoskelet Med. – 2010. – v.27. – p.351-354115. Kelaidi C., Rollot F., Park S., Tulliez M.
Response to antiviral treatment in hepatitis C virus-associatedmarginal zone lymphomas. // Leukemia. – 2004. - v.18. – p.1711-1717.116. Lake-Bakaar G., Jacobson I., Talal A. B cell activating factor (BAFF) in the natural history of chronichepatitits C virus liver disease and mixed cryoglobulinaemia. // Clinical and experimental immunologi.
–2012. – v.170. – p.231-237.117. Lamprecht P., Moosig F., Cause A et al. Birmingham vasculitis activity score, disease extent index andcomplement factor C3c reflect disease activity best in hepatitis C virus-associated cryoglobulinemicvasculitis.// Clin Exp Rheumatol.- 2000. v.18. – p319-325118. Landau D.A., Saadoun D., Calabrese L.H., Cacoub P. The pathophysiology of HCV-induced B-cellclonal disorders. // Autoimm Rew.
- 2007. - v.6. – p.581-587.119. Landau D.A., Saadoun D., Halfon P. et al. Relapse of hepatitis C virus-associated mixedcryoglobulinemia vasculitis in patients with sustained viral response. // Arthritis Rheumatism. – 2008. –v.58. – p. 604-611.120. Landau D.A., Rosenzwajg M., Saadoun D.
The B lymphocyte stimulator receptor-ligand system inhepatitis C virus-induced B cell clonal disorders. // Ann Rheum Dis. – 2009. – v.68. – p.337-381.121. Landau D.A., Scerra S. et al. Causes and predictive factors of mortality in cohort of patients withhepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy. // J Rheumatol. –2010. – v.37. – p.615-621.122. Lauletta G., Russi S., Conteduca V., Sansonno L. Hepatitis C virus infection and mixedcryoglobulinemia.
// Clin Dev Immunol. – 2012. – p.876 - 935.123. Lerner A, Watson C.Studies of cryoglobulins. I. Unusual purpura associated with the presence of a highconcentration of cryoglobulin (cold precipitable serum globulin).//Am.J.M.Sc. -1947.- v.214. –p.410124. Levine J.W., Gota C., Fessler B.J., Calabrese L.H.
Persistent cryoglobulinemic vasculitis followingsuccessful treatment of hepatitis C virus. // J Rheumatol. – 2005. – v.32. – p.1164-1171.125. Levo V., Gorevic P.D., Kassab H.Y. et al. Association between hepati tis В virus and essentialmixed cryoglobulinemia.// N. Engl. J. Med.. 1977.- v.297.- p.946-947126. LoSpalluto J., Dorward В., Miller W. Cryoglobulinemia based on interaction between agamma macroglobulin and 7S gammaglobulin. // Am.
J. Med. - 1962. – v.32. – p.142-145.127. Luqmani R.A., Bacon P.A., Moots R.J. et al. Birmingham vasculitis activity score (BVAS) in systemicnecrotizing vasculitis.// Q.J.Med. -1994. – v.87. –p.671-681128. Martyak L.A., Yeganen M., Saab S. Hepatitis C and lymphoproliferative disorders: from mixedcryoglobulinemia to non-Hodgkin's lymphoma. // Clinical Gastroenterol Hepatology. - 2009. – v.7.
– p.900-905.129. Marcucci F., Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms oftumorigenesis, and therapeutic opportunities. // Blood. – 2011. – v.6. – p. 117- 134.130. Mazzaro C., Lacchin T., Moretti M. et al. Effects of two different alpha-interferon regimens on clinicaland virological findings in mixed cryoglobulinemia. // Clin Exp Rheumatol. - 1995.
– v.13 (Suppl 13). –p.181-185.131. Mazzaro C., Zorat F., Comar C. et al. Interferon plus ribavirin in patients with hepatitis C virus positivemixed cryoglobulinemia resistant to interferon. // J Rheumatol. – 2003. – v.30. – p.1775-1781.147132. Mazzaro C., Zorat F., Caizzi M., Donada C. Treatment with peg-interferon alfa-2b and ribavirin ofhepatitis C virus-associated mixed cryoglobulinemia: a pilot study. // J Hepatol. – 2005. – v.42. – p.632640.133.
Mazzaro C., De Re V., Spina V. et al. Pegylated-interferon plus ribavirin for HCV-positive indolentnon-Hodgkin's lymphomas. // Br J Hematol. – 2009. – v.145. – p. 255-257134. Mazzarro C., Monti G., Saccardo F. Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCVpositive mixed cryoglobulinemia: a multicentre open-label study. // Clin Exp Rheumatol. - 2011. - v.29.– p.933-974.135.
McCarthy M., Ortega M.R. Neurological complications of hepatitis C infection. // Curr Neurol NeurosciRep. – 2012. – v.12. – p.642-696.136. Meltzer M., Franklin E.C, Elias K., et al. Cryoglobulinemia: a clinical and laboratory study. // Am JMed. – 1966. – v.40. - p.837-856.137. Misiani R., Bellavita P. Fenili D. et al.
Interferon alpha-2a therapy in cryoglobulinemia associated withhepatitis C virus. N.Eng.J.Med. – 1994. –v.330. –p.751-756138. Monaco S., Ferrari S., Gajofatto A. HCV-related nervous system disorders. // Clin Dev Immunol. –2012. – p.2361-2409.139. Monti G., Saccardo F., Pioltelli P., Rinaldi G. The natural history of cryoglobulinemia: symptoms atonset and during follow-up. A report by the Italian Group for the Study of Cryoglobulinemias (GISC).
//Clin Exp Rheumatol. – 1995. - v.13(Suppl 13). – p.129-162.140. Monti G., Pioltelli P., Saccardo F., Campanini M, et al. Incidence and characteristics of non-Hodgkinlymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixedcryoglobulinemias. // Arch Intern Med. – 2005. – v.165. – p.101-106.141.
Mukhtyar C., Lee R., Broun D. et al. Modification and validation of the Birmingham vasculitis activityscore (Version 3).// Ann Rheum Dis .-2009.-v68.-p.1827-1832142. Nicolau A., Tănăsescu R., Bălănescu E. Hepatitis C virus-mixed cryoglobulinemia-lymphomarelationship. // Rom J Intern Med. - 2011. – v.49. – p. 3-13.143. Nicot F., Kamar N., Mariamé B. No evidence of occult hepatitis C virus (HCV) infection in serum ofHCV antibody-positive HCV RNA-negative kidney-transplant patients. // Transpl.
Int. – 2010. – v.23. –p.594-601144. Nieters A, Kallinovski B, Brennan P et al. Hepatitis C and risk of lymphoma: results of Europeanmulticenter case-control study EPILYMH. Gastroenterology 2006; 131: 1879-1886145. Palazzi C., D’Agnelo S, Oliveri I. Hepatitis C virus-related arthritis.// Autoimmun Rev. – 2008. - v.8. –p. 48-51146.
Peveling-Oberhag J, Arcaini L. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology,molecular signature and clinical management.// J Hepatol. – 2013. – v.59(1). – p.169-246.147. Pellicelli A.M., Marignani M., Zoli V. et al. Hepatitis C related B cell subtypes in non Hodgkin’slymphoma. // World J Hepatol.- 2011. – v.3. – p. 277-284.148. Petrarca A., Rigacci L., Caini P., Colagrande S. Safety and efficacy of rituximab in patients withhepatitis C virus-related mixed cryoglobulinemia and severe liver disease. // Blood.- 2010.- v.116.
–p.335-377.149. Pham T.N., Michalak T.I. Occult persistence and lymphotropism of hepatitis C virus infection. // WorldJ Gastroenterol.- 2008. - v.14. – p.2789-2882.150. Pham T.N., Coffin C.S., Churchill N.D. Hepatitis C virus persistence after sustained virologicalresponse to antiviral therapy in patients with or without past exposure to hepatitis B virus. // J ViralHepat. – 2012. – v.19. – p.103-114.151.
Pietrogrande M., De Vita S., Zignego A.L., Pioltelli P., Sansonno D. Recommendations for themanagement of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. // AutoimmunRev. – 2011. – v.10. – p.444-498.152. Quartuccio L., De Marchi G., Fabris M., De Vita S. Development of type II mixed cryoglobulinaemicsyndrome after effective and persistent hepatitis C virus eradication. // Rheumatology (Oxford). – 2007. v.46.
– p.367-375.153. Quartuccio L., Petrarca A., Mansutti E. Efficacy of rituximab in severe and mild abdominal vasculitis inthe course of mixed cryoglobulinemia. // Clin Exp Rheumatol. – 2010. – v.28(1 Suppl 57). – p.84-91.148154.Ramos-Casals M.,Robles A., Brito-Zeron P. et al. Life-threatening cryoglobulinemia:clinical and immunological characterization of 29 cases.// Semin Artritis Rheum. 2006.-v.36.– p.189-196155.Rodriguez-Inigo E., Casquero M., Bartolome J., et al. Hepatitis С virus RNA inkidney biopsies from infected patients with renal diseases. // J.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
